The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction – baseline. failure.9 A trial of ivabradine involving patients well as for the fidelity of this report to the trial tricular systolic dysfunction (BEAUTIFUL). The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction.
|Published (Last):||20 November 2013|
|PDF File Size:||1.38 Mb|
|ePub File Size:||19.17 Mb|
|Price:||Free* [*Free Regsitration Required]|
Read your latest personalised notifications Sign in No account yet? Ivabradine is approved in Europe for the symptomatic treatment of chronic stable angina in coronary artery disease CAD patients who are in normal sinus rhythm and have a resting heart rate of 70 bpm or greater. The mean heart rate in these patients was 71 bpm and half of the patients had a heart rate more than 70 bpm. No significant difference was seen with regards to the primary outcome.
Reduction in heart rate with ivabradine does not improve cardiac outcomes in all patients with stable coronary artery disease and left-ventricular systolic dysfunction, but could be used to reduce the incidence of coronary artery disease outcomes in a subgroup of patients who have heart rates of 70 bpm or greater.
Classified as close Confirmation 1. However, it did reduce secondary endpoints: In patients in normal sinus rhythm who cannot tolerate target doses of beta blockers or who experience high heart rates despite optimal beta blocker therapy, ivabradine may be a useful addition to standard heart failure therapy.
Don’t miss out Read your latest personalised notifications Ok, got it. However, it did reduce secondary endpoints: Between December,and December,we screened 12 patients at centres in 33 countries. Differences between drugs within the class Ivabradine is the only selective I f channel inhibitor to date. Consider the following examples, but note that this is not an exhaustive list: We aimed to test whether lowering the heart rate with ivabradine reduces cardiovascular death and morbidity in patients with coronary artery disease ivabrarine left-ventricular systolic dysfunction.
The maximum recommended dose is 7. I am a Faculty Member who recommended this article. The Cardiology Advisor Update. Patients may take ivabradine in combination with standard therapy, including beta blockers, or when beta blocker therapy is contraindicated or not tolerated. I would like to receive updates when further comments, recommendations, or dissenting opinions are publishing on this article. F does not store recipient email addresses. You must be a registered member of The Cardiology Advisor to post a comment.
Median follow-up was 19 months IQR Recommended dose adjustment according to heart rate In patients with a history of conduction defects, or other patients in whom bradycardia could lead to hemodynamic compromise, initiate therapy at 2.
With the BEAUTIFUL Results, Procoralan* (ivabradine) is the First Antianginal Tr
Mean heart rate at baseline was The primary endpoint was a composite of cardiovascular death, admission to hospital for acute myocardial infarction, and admission to hospital for new onset or worsening heart failure. Ivabradine specifically inhibits the I f current in the sinoatrial node to lower heart rate, without affecting other aspects of cardiac function.
In a prespecified subgroup of patients with heart rate of 70 bpm or greater, ivabradine treatment did not affect the primary composite outcome hazard ratio 0. Additional warnings and precautions include: To date, there are no well-established, head-to-head studies comparing ivabradine with other rate-lowering medications used in heart failure, such as digoxin.
User comments must be in English, comprehensible and relevant to the article under discussion.
We analysed patients by intention to treat. Due to having a narrow therapeutic index window in heart failure, in contrast to ivabradine, digoxin requires close monitoring with regards to serum drug levels, renal function, and electrolytes. F does not claim any ownership in the Material that you or any other user posts.
BEAUTIFUL TRIAL –
This Agreement shall begin on the date hereof. Over igabradine, patients were randomized and followed for about The recommended starting dose of ivabradine is 5 mg by mouth twice daily with meals. Accordingly you may only post Material that you have the right to do so. You are an Editor for the journal in which the article is published.
F reserves the right to monitor all Material and to remove any Material which it considers in its absolute discretion to be unlawful, inappropriate, offensive or otherwise in breach of these Terms and Conditions. The primary endpoint was a composite of cardiovascular death, admission to hospital for acute myocardial infarction, and admission to hospital for new onset or worsening heart beautifhl. Administration The recommended starting dose of ivabradine is 5 mg by mouth twice daily with meals.
Sign in to My ESC. By posting or uploading Material you warrant and represent that: Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality.
The secondary endpoints were all-cause hospital admission, hospital admission for worsening heart failure, any cardiovascular hospital admission, or composite cardiovascular death, or hospital admission for worsening heart failure, or hospital admission for non-fatal myocardial infarction MI.
Munich, Germany, 31 August, Register Already registered with FPrime? Alternative approaches To date, there are no well-established, head-to-head studies comparing ivabradine with other rate-lowering medications used in heart failure, such as digoxin. Disclosures Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality.
The efficacy of ivabradine in heart failure patients is demonstrated via a randomized, multi-center, double-blind, placebo-controlled, parallel-group trial – SHIFT – which was published in Between December,and December,we screened 12 patients at centres in 33 countries.
The dose of beta blockers was maintained during the trial; no reduction in dosage was observed while titrating ivabradine. Adjust the dose as needed based on resting heart rate and tolerability.